Rare but serious concerns include pancreatitis, gallbladder problems, and potential thyroid C-cell tumors (observed in rodent studies, not confirmed in humans)
A licensed healthcare provider reviews your eligibility
In Eli Lilly's pivotal Phase 3 ATTAIN clinical trialsthe studies that led to FDA approvalparticipants taking orforglipron achieved average body weight reductions of approximately 7.9% to 8.7% over 36 to 40 weeks, depending on the dosing
Potential benefits of combining intermittent fasting and GLP-1 medications Pairing intermittent fasting with GLP-1 medications may offer several synergistic benefits: Enhanced weight loss: Both approaches reduce appetite and calorie intake, potentially leading to faster and more sustainable weight loss
The monitoring programme allows us to look at those substances in urine samples and see if we detect patterns of abuse
She wanted a solution that addressed more than just the numbers on the scale